Slideshow
Author(s):
New studies shed light on the potential role of monoclonal antibodies in migraine prophylaxis and in Parkinson disease and on a common genetic pathway shared by PD and autoimmune diseases.
Atogepant Appears More Cost Effective and Efficacious Than Rimegepant, Indirect Comparison Data Suggests
Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease
Neurology Unwrapped: 2024’s Most Intriguing Conversations
NeurologyLive®: Mapping Out Our 2025 Conference Journey
FDA Action Update, December 2025: Approval, Designations, and Clinical Hold